Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 1
2018 4
2019 13
2020 9
2021 10
2022 11
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for piergiorgio malagoli
Search for Piergiorigio Malagoli instead (1 results)
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).
Gargiulo L, Narcisi A, Ibba L, Balato A, Bianchi L, Brianti P, Buononato D, Burlando M, Caldarola G, Campanati A, Campione E, Carrera CG, Carugno A, Cristaudo A, Cusano F, Dapavo P, Dattola A, De Simone C, Gaiani FM, Gisondi P, Giunta A, Loconsole F, Maione V, Mortato E, Marzano AV, Maurelli M, Megna M, Mercuri SR, Offidani A, Orsini D, Parodi A, Pellacani G, Potestio L, Quaglino P, Richetta AG, Romano F, Sena P, Venturini M, Malagoli P, Costanzo A. Gargiulo L, et al. Among authors: malagoli p. Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37614958 Free PMC article.
Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes.
Malavazos AE, Meregalli C, Sorrentino F, Vignati A, Dubini C, Scravaglieri V, Basilico S, Boniardi F, Spagnolo P, Malagoli P, Romanelli P, Secchi F, Iacobellis G. Malavazos AE, et al. Among authors: malagoli p. Endocrinol Diabetes Metab Case Rep. 2023 Aug 8;2023(3):23-0017. doi: 10.1530/EDM-23-0017. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 37551923 Free PMC article.
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: malagoli p. Front Immunol. 2024 Jan 11;14:1341708. doi: 10.3389/fimmu.2023.1341708. eCollection 2023. Front Immunol. 2024. PMID: 38274801 Free PMC article.
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort.
Viola R, Mastorino L, Megna M, Damiani G, Gisondi P, Argenziano G, Peris K, Prignano F, Burlando M, Conti A, Loconsole F, Malagoli P, Zalaudek I, Cacciapuoti S, Bellinato F, Balato A, De Simone C, Chersi K, Ortoncelli M, Quaglino P, Dapavo P, Ribero S. Viola R, et al. Among authors: malagoli p. Int J Dermatol. 2024 Mar;63(3):351-358. doi: 10.1111/ijd.17005. Epub 2024 Jan 5. Int J Dermatol. 2024. PMID: 38178802
Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience.
Gargiulo L, Ibba L, Vignoli CA, Ferrucci SM, Mercuri SR, Malagoli P, Marzano AV, Barbareschi M, Bianchi VG, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: malagoli p. J Dermatolog Treat. 2023 Dec;34(1):2268764. doi: 10.1080/09546634.2023.2268764. Epub 2023 Oct 11. J Dermatolog Treat. 2023. PMID: 37818648 Free article. No abstract available.
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
Chiricozzi A, Costanzo A, Fargnoli MC, Malagoli P, Piaserico S, Amerio P, Argenziano G, Balato N, Bardazzi F, Bianchi L, Carrera CG, Conti A, Dapavo P, De Simone C, Loconsole F, Lo Schiavo A, Malara G, Musumeci ML, Parodi A, Peris K, Prignano F, Rongioletti F, Talamonti M, Potenza C. Chiricozzi A, et al. Among authors: malagoli p. Eur J Dermatol. 2021 Feb 1;31(1):3-16. doi: 10.1684/ejd.2021.3965. Eur J Dermatol. 2021. PMID: 33648915 Review.
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis.
Gisondi P, Geat D, Conti A, Dapavo P, Piaserico S, De Simone C, Bianchi L, Costanzo A, Malagoli P, Malara G, Micali G, Naldi L, Offidani A, Patrizi A, Prignano F, Parodi A, Rongioletti F, Calzavara-Pinton P, Girolomoni G. Gisondi P, et al. Among authors: malagoli p. Expert Rev Clin Immunol. 2020 Jun;16(6):591-598. doi: 10.1080/1744666X.2020.1771182. Epub 2020 Jun 4. Expert Rev Clin Immunol. 2020. PMID: 32419534 Review.
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients.
Ciolfi C, Balestri R, Bardazzi F, Burlando M, Chersi K, Costanzo A, Dapavo P, Gisondi P, Malagoli P, Pizzolato M, Rech G, Russo FP, Battistella S, Piaserico S. Ciolfi C, et al. Among authors: malagoli p. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1203-e1207. doi: 10.1111/jdv.19186. Epub 2023 May 18. J Eur Acad Dermatol Venereol. 2023. PMID: 37170951 No abstract available.
Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study).
Chiricozzi A, Megna M, Giunta A, Carrera CG, Dapavo P, Balato A, Malagoli P, Mazzoccoli S, Parodi A, Sabatino S, Buzzoni C, Huang CH, Narcisi A. Chiricozzi A, et al. Among authors: malagoli p. J Dermatolog Treat. 2023 Dec;34(1):2246606. doi: 10.1080/09546634.2023.2246606. J Dermatolog Treat. 2023. PMID: 37587870 Free article.
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.
Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E. Russo F, et al. Among authors: malagoli p. Clin Cosmet Investig Dermatol. 2023 Dec 12;16:3561-3574. doi: 10.2147/CCID.S416149. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 38107670 Free PMC article.
61 results